Читаем Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний полностью

Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

Бастиан Блоэм , Майкл Окун , Рэй Дорси , Тодд Шерер

39. Tracking LRRK2-Parkinson’s progression for better trial design. Alzforum. March 23, 2018. www.alzforum.org/news/research-news/ tracking-lrrk2-parkinsons-progression-better-trial-design. Accessed November 30, 2018.

40. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37.

41. Там же.; Stott S. New LRRK2 results: game changer? Science of Parkinson’s. July 25, 2018. https://scienceofparkinsons.com/2018/07/25/lrrk-2. Accessed June 27, 2019; Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).

42. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).

43. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, Mc Inerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics. 2004;41(12):937–940.

44. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Frequency of known mutations in earlyonset Parkinson disease: implication for genetic counseling: the Consortium on Risk for Early-Onset Parkinson Disease study. Archives of Neurology. 2010;67(9):1116–1122.

45. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurology. 2012;11(11):986–998.

46. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Current Neurology and Neuroscience Reports. 2010;10(3):190–198.

47. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/ jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.

48. The Silverstein Foundation in the News. Silverstein Foundation for Parkinson’s with GBA. www.silversteinfoundation.org/in-the-news. Accessed March 29, 2019.

49. On the money. CNBC. August 19, 2017. https://archive.org/details/ CNBC_20170819_ 093000_On_the_Money.

50. Silverstein Foundation for Parkinson’s with GBA. 2018. www. silversteinfoundation.org. Accessed November 30, 2018.

51. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/ jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.

52. About Prevail. Prevail Therapeutics. www.prevailtherapeutics.com/ about-prevail. Accessed November 30, 2018.

53. Silveira CRA, MacKinley J, Coleman K, et al. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurology. 2019;19(1):20–20; McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014; 137(5): 1481–1495; Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson’s disease: from genetics to the clinic. Movement Disorders. 2018;33(5):684–696.

54. Kuhl MM. First trial begins testing drug in people with GBA mutation. FoxFeed Blog. February 14, 2017. www.michaeljfox.org/news/first-trial-begins-testing-drug-people-gba-mutation. Accessed June 27, 2019.

55. Там же.; Sanofi initiates phase 2 clinical trial to evaluate therapy for genetic form of Parkinson’s disease [пресс-релиз]. Business Wire. February 14, 2017. www.businesswire.com/ news/home/20170214005771/en/ Sanofi-Initiates-Phase-2-Clinical-Trial-Evaluate. Accessed June 27, 2019; A global study to assess the drug dynamics, efficacy, and safety of GZ/ SAR402671 in Parkinson’s disease patients carrying a glucocerebrosidase (GBA) gene mutation (MOVES-PD). US National Library of Medicine: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/ NCT02906020. Updated March 14, 2019. Accessed March 29, 2019; Sardi SP, Viel C, Clarke J, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(10):2699–2704.

56. A global study to assess the drug dynamics, efficacy, and safety of GZ/ SAR402671 in Parkinson’s disease patients carrying a glucocerebrosidase (GBA) gene mutation (MOVES-PD). US National Library of Medicine: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/ NCT02906020. Updated March 14, 2019. Accessed March 29, 2019.

57. Vision and mission. Parkinson’s Foundation. www.parkinson.org/about-us/vision-and-mission. Accessed March 29, 2019.

Перейти на страницу: